TrialHuman vaccines & immunotherapeutics2018

Safety, tolerability and immunogenicity of the ExPEC4V (JNJ-63871860) vaccine for prevention of invasive extraintestinal pathogenic Escherichia coli disease: A phase 1, randomized, double-blind, placebo-controlled study in healthy Japanese participants.

Megumi Inoue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.